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Abstract
Background and Aims: Non-motor symptoms (NMS) are important manifestations of Parkinson’s disease (PD) that reduce
patients’ health-related quality of life. Some NMS may also be caused by age-related changes, or manifested as a
psychological reaction to a chronic neurological condition. This case-control study compared the NMS burden among PD
patients, healthy controls and hemifacial spasm (HFS) patients. In addition, we determined the NMS that discriminated
between PD and non-PD subjects.
Methods: 425 subjects were recruited from a tertiary hospital in Singapore (200 PD patients, 150 healthy controls and 75
HFS patients). NMS burden in subjects was measured using the Non-Motor Symptoms Scale (NMSS).
Results: NMSS total score was significantly higher in PD patients (37.962.6) compared to healthy controls (11.260.9)
(p,0.0001) and HFS patients (18.062.1) (p,0.0001). In addition, NMSS total score was significantly higher in HFS patients
compared to healthy controls (p= 0.003). PD patients experienced a higher NMS burden than healthy controls in all
domains, and a higher NMS burden than HFS patients in all but attention/memory and urinary domains. NMS burden for
HFS and healthy controls differed only in the sleep/fatigue and urinary domains. Using stepwise logistic regression,
problems of ‘constipation’, ‘restless legs’, ‘dribbling saliva’, ‘altered interest in sex’ and ‘change in taste or smell’ were found
to have significant discriminative power in differentiating between PD patients and healthy controls and between PD
patients and HFS patients.
Conclusion: PD patients experienced a greater overall NMS burden compared to both healthy controls and HFS patients.
HFS patients demonstrated a higher NMS burden than controls, and some NMS may be common to chronic neurological
conditions while others are more specific to PD. Differentiating patients using NMS domains may help refine the clinical
management of NMS in PD patients.
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Introduction
Non-motor symptoms (NMS) are important manifestations of
Parkinson’s disease (PD) in addition to the cardinal motor
symptoms of bradykinesia, tremor, rigidity and postural instability,
and some eventually become prominent causes of disability [1,2].
The current understanding is that NMS results from Lewy body
pathology involving regions of the nervous system outside the
substantia nigra, [3] which begins in the olfactory bulb and
medulla, and progresses through the central nervous system from
the medulla in a predictable ascending sequence described by the
Braak stages [3–5]. The peripheral autonomic nervous system is
also involved [3,6]. Sufficiently disrupted neurotransmitter path-
ways would theoretically result in the clinical manifestation of
NMS. Antiparkinsonian medications may also precipitate, exac-
erbate or relieve NMS, [7,8] adding complexity to NMS
characterization and treatment. NMS have been shown to have
a significant impact on PD patients’ health-related quality of life
that may be greater than that of motor symptoms [9–13].
NMS characterization is not straightforward: The range of
NMS is vast, and clinical correlation with neuropathological
findings is partial and not fully established [5]. Furthermore, NMS
may be caused by normal age-related changes or other diseases, or
develop as a psychological reaction to a chronic disease. The Non-
Motor Symptoms Scale (NMSS) is a clinically validated instrument
that comprehensively assesses the burden of 30 NMS relevant in
PD [14,15]. It calculates a score for each NMS as a function of
severity and frequency to reflect its burden. It is suitable for
assessing a wide range of NMS and evaluating which ones
clinically manifest differentially in PD patients. To date, there exist
few case-controls studies using the NMSS to compare the NMS
burden between PD patients and healthy controls, [16,17] and
none have investigated its utility in detecting NMS which may
develop as a reaction to suffering from a chronic neurological
disease.
We utilized the NMSS to compare the NMS burden between
non-demented idiopathic PD patients, healthy controls and
hemifacial (HFS) patients, and to identify which of the 30 NMS
PLOS ONE | www.plosone.org 1 February 2013 | Volume 8 | Issue 2 | e49596
evaluated in the scale best discriminate between PD patients and
the two groups of non-PD subjects. HFS was chosen as a
comparator because it is a chronic, localized neurologic disease
which is not known to have pathology such as that exhibited in a




200 idiopathic Parkinson’s disease (PD) patients, diagnosed
according to the UK PD Brain Bank criteria, [18] were recruited
from the movement disorder outpatient clinics in Singapore
General Hospital (SGH), a tertiary referral center. PD patients
with significant cognitive impairment, defined as scoring 5 points
or less (out of a maximum of 10 points) on our locally validated
Elderly Cognitive Assessment Questionnaire (ECAQ), [19] were
excluded. 150 healthy controls frequency-matched for age (6
5 years) and sex also participated. A third group of 75 similarly
matched patients diagnosed with hemifacial spasm (HFS) (based
on the presence of tonic and/or clonic contractions of facial
muscles innervated by the ipsilateral facial nerve) [20] and
receiving botulinum toxin treatment from the SGH movement
disorders outpatient clinic was also recruited. Only subjects of
Asian ethnicity were included. Any subject with a severe chronic
debilitating condition (e.g. renal failure requiring dialysis, conges-
tive cardiac failure, diabetes mellitus with advanced complications,
other CNS disorders), or with terminal illness was excluded.
Hypertension, hyperlipidemia, controlled diabetes mellitus and
ischemic heart disease are common conditions that do not cause
excessive distress in general, and these conditions were also not
excluded. The study was approved by the SingHealth Centralised
Institutional Review Board.
Data collection and assessments
Demographic data was collected from subjects. Non-motor
symptoms (NMS) were assessed using the Non-Motor Symptoms
Scale (NMSS) [14]. This scale evaluates 30 NMS relevant in PD,
grouped into 9 domains (cardiovascular domain, sleep/fatigue,
mood/cognition, perceptual problems/hallucinations, attention/
memory, gastrointestinal, urinary, sexual function and miscella-
neous). Each item in the NMSS rates a NMS according to its
severity (scored from 0 to 3) and frequency (scored from 1 to 4)
over the past month, and these two ratings are multiplied to give a
final item score representing the burden of that symptom. A
domain score is calculated for each domain as the sum of the item
scores within that domain. The NMSS total score, the sum of all
the item scores, reflects the overall NMS burden in a subject. The
presence of each NMS in subjects was also coded.
PD patients underwent further clinical assessment for disease
severity with Part III (motor section) of the Unified Parkinson’s
Disease Rating Scale (mUPDRS) [21] and the modified Hoehn
and Yahr (H&Y) staging scale [22]. The levodopa equivalent daily
dose (LEDD) was calculated according to standardized formulae,
using terms for levodopa, dopamine agonists and entacapone:
LEDD (mg/day) = ([ L-dopa (mg)] + [Controlled release L-dopa
(mg)] 60.75) (61.33 for L-dopa doses taken together with
entacapone) + [pramipexole (mg)6100] + [ropinirole (mg)620]
+ [piribedil (mg)61] + [bromocriptine (mg)610] [23].
Statistical analysis
Baseline characteristics for continuous variables were compared
across all groups using the Kruskal-Wallis test, and pair-wise
comparisons were performed using the Wilcoxon rank-sum test.
Categorical variables were compared using the chi-square test.
Continuous variables for baseline characteristics are summarized
as mean 6 standard deviation; categorical variables are summa-
rized as percentages.
Frequency distribution plots of NMSS scores, whether for each
item, domain or total score, consistently exhibited highly right-
skewed, heavy tailed distributions resembling those of over-
dispersed counting distributions. In the search for an acceptable
statistical model, various error distributions and link functions
were evaluated in the context of a generalized linear model
(GLIM). The best fitting (lowest AIC) model for comparing NMSS
scores (item, domain and total) between the three groups
incorporated the negative binomial error distribution in conjunc-
tion with the log link function. An analysis comparing NMSS total
score among the three groups incorporated age, sex, presence of
hypertension, hyperlipidemia, diabetes mellitus and ischemic heart
disease in the model as potential confounders. The only one found
to be statistically significant was age. Because an attempt was made
to match groups on age and sex, both variables were included in
the final model. The Tukey-Kramer approach was used to adjust
the type I error for multiple pair-wise comparisons, and tabulated
p-values reflect the adjustment. Comparison of NMSS scores
between PD patients of the different disease (H&Y) stages was
performed using the same methodology. Logistic regression
analysis was used to compare prevalence of NMS among groups,
controlling for age and sex. In addition to age and sex, diabetes
mellitus was a statistically significant factor in the comparison of
NMSS scores and prevalence of the symptom of ‘problems having
sex’ in the sexual function domain. All reported prevalence values
and mean NMSS scores are model-based, predicted proportions
and least squares means (6 standard errors), respectively, adjusted
for covariates. Stepwise logistic regression (significance level to
enter = significance level to remove = 0.05) was used to select
non-motor symptoms in the NMSS which best discriminated
between PD patients and healthy controls, and between PD
patients and HFS patients.
In a subgroup analysis of PD patients, Spearman’s rank
correlation (rho) was used to investigate univariate associations
between the NMSS total score and selected variables. Analysis of
covariance was used to determine clinical factors associated with
NMSS total scores and domain scores–H&Y stage was grouped
into 3 classes: stages 1–1.5, 2–2.5, and 3–5.
Statistical significance was set at p#0.05. All statistical analyses
were performed using the SAS software (version 9.2; North
Carolina: SAS Institute Inc.).
Results
Demographic data and PD patient characteristics
The mean age was 64.469.7 years in the PD patient group,
60.7611.3 in the healthy control group, and 62.2611.1 in the
HFS patient group. 54.5% of PD patients, 52.0% of healthy
controls and 49.3% of HFS patients were male. Demographic and
comorbidity data are summarized in Table 1.
In the PD patient group, mean disease duration was
6.064.5 years and mean mUPDRS score was 28.4613.2. The
median H&Y stage was 2.5. 16.5% of PD patients were in H&Y
stages 1 – 1.5, 60.5% in stages 2 – 2.5, 21% in stage 3, and 2% in
stages 4 – 5. 78.5% of patients were on levodopa and 20.5% were
on a dopamine agonist; 11.5% were on both levodopa and a
dopamine agonist. 11.0% were on neither levodopa nor a
dopamine agonist. The mean levodopa equivalent daily dose
(LEDD) was 369.26295.5 mg/day. For patients on dopamine
agonists, the mean dopamine agonist daily dose (in levodopa-
Non-Motor Symptoms in Parkinson’s Disease
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equivalent units) was 67.8648.5 mg/day. The mean disease
duration in the HFS patient group was 10.965.3 years.
NMS burden
Least squares (LS) mean NMSS total and domain scores
adjusted for age and sex are presented in Table 2. The adjusted
mean NMSS total score (reflecting overall NMS burden) was
significantly higher in the PD patients compared to healthy
controls (37.962.6 vs. 11.260.9 respectively, p,0.0001) and HFS
patients (37.962.6 vs. 18.062.1, p,0.0001). The adjusted mean
NMSS total score in HFS patients was also significantly higher
than that of healthy controls (p=0.003).
All of the domain scores were significantly higher in PD patients
than in healthy controls. Sleep/fatigue and urinary domain scores
were significantly higher in the HFS group compared to healthy
controls. Item scores were higher in HFS patients than in healthy
controls for the symptoms of ‘fatigue’ (1.860.3 vs. 0.860.1,
p=0.003), ‘forget to do things’ (1.160.2 vs 0.660.1, p=0.050)
and ‘urinary urgency’ (1.160.3 vs. 0.460.1, p=0.023). Domain
scores were significantly higher in the PD patient group compared
to HFS patients, except for the attention/memory and urinary
domains. The item scores for ‘fainting (secondary to orthostatic
hypotension)’, ‘flat mood’, ‘delusions’, and ‘problems having sex’
did not differ significantly between the three groups. Symptoms
with item scores that were significantly higher in PD patients
compared to healthy controls (C) but not when compared to HFS
patients included ‘difficulty falling or staying asleep’ (PD: 2.360.4,
C: 0.960.2, HFS: 1.760.4; p=0.001 for PD vs. C), ‘feel nervous’
(PD: 1.460.3, C: 0.360.1, HFS: 0.760.2; p,0.0001 for PD vs.
C), ‘forgetting things or events’ (PD: 1.360.1, C: 0.860.1, HFS:
1.160.2; p=0.005 for PD vs. C), ‘forgetting to do things’ (PD:
1.060.1, C: 0.660.1, HFS: 1.160.2; p=0.020 for PD vs. C),
‘(urinary) urgency’ (PD: 1.360.2, C: 0.460.1, HFS: 1.160.3;
p=0.0002 for PD vs. C) and ‘urinary frequency’(PD: 1.360.2, C:
0.460.1, HFS: 1.060.3; p=0.001 for PD vs. C). The symptoms of
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Sex (% male) 54.5 52.0 49.3 0.730
Hypertension (%) a, b 41.5 29.3 46.7 0.017
Hyperlipidemia (%) 33.5 24.7 33.3 0.170
Diabetes mellitus (%) a, b 18.0 7.3 16.0 0.014
Ischemic heart disease (%) 7.5 6.0 4.0 0.557
aSignificant difference between healthy control group and PD patient group (p,0.05).
bSignificant difference between control group and disease control group (p,0.05).
doi:10.1371/journal.pone.0049596.t001
Table 2. Comparisons of estimated NMSS total and domain scores1 by study group.
Study Group
F-test
p-value Pair-wise Comparison p-values
3
PD C HFS PD vs C PD vs HFS HFS vs C
NMSS total score 37.9 (62.6) 11.2 (60.9) 18.0 (62.1) ,0.0001 ,0.0001 ,0.0001 0.003
Domains
Cardiovascular domain 1.0 (60.2) 0.3 (60.1) 0.3 (60.1) ,0.0001 ,0.0001 0.001 0.884
Sleep/fatigue domain 8.2 (60.8) 2.5 (60.3) 4.3 (60.7) ,0.0001 ,0.0001 0.002 0.016
Mood domain 9.2 (61.2) 1.9 (60.3) 3.5 (60.8) ,0.0001 ,0.0001 0.001 0.064
Perceptual problems/
hallucinations domain
1.0 (60.2) 0.05 (60.02) 0.1 (60.1) ,0.0001 ,0.0001 0.0003 0.642
Attention/memory
Domain
3.5 (60.3) 1.9 (60.2) 2.9 (60.5) 0.0003 0.0002 0.536 0.091
Gastrointestinal domain 3.2 (60.5) 0.2 (60.1) 0.3 (60.1) ,0.0001 ,0.0001 ,0.0001 0.924
Urinary domain 5.1 (60.6) 1.8 (60.3) 3.4 (60.6) ,0.0001 ,0.0001 0.158 0.016
Sexual function domain2 1.4 (60.2) 0.8 (60.1) 0.7 (60.2) 0.003 0.010 0.028 0.953
Miscellaneous domain 5.1 (60.6) 1.6 (60.2) 2.0 (60.4) ,0.0001 ,0.0001 ,0.0001 0.648
PD: Parkinson’s disease patients; C: Healthy controls; HFS: Hemifacial spasm patients.
1Estimated mean scores adjusted for age and sex (6 standard error) using GLIM negative binomial model 2Estimated percentages adjusted for age, sex and presence of
diabetes mellitus (6 standard error) using logistic regression model.
3Tukey-Kramer adjusted p-values.
doi:10.1371/journal.pone.0049596.t002
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‘fatigue’, ‘difficulty falling or staying asleep’, ‘nocturia’ and ‘pain’
contributed most to NMS burden for all three groups of subjects.
NMS prevalence
The prevalence of NMSS domains (presence of at least one
symptom in the respective domain) in our sample are shown in
Table 3. Prevalence of cardiovascular symptoms, ‘delusions’,
‘concentration problems’, ‘forgetting things or events’, and of
‘pain’ did not differ between the three groups (data not shown).
Sleep/fatigue symptoms (‘fatigue’ (46.7% vs. 28.9%, p=0.009))
and ‘difficulty falling/staying asleep’ (46.8% vs. 23.1%, p=0.001)),
mood symptoms (‘loss of interest in the surroundings’ (18.4% vs.
6.0%, p=0.006), ‘lack motivation’ (22.7% vs. 8.7%, p=0.005),
‘feel nervous’ (25.9% vs. 9.7%, p=0.002) and ‘difficulty experi-
encing pleasure’ (21.1% vs. 6.5%, p=0.002)) and the symptom of
‘forget to do things’ (51.0% vs. 33.9%, p=0.016) were more
prevalent in HFS patients compared to controls.
Clinical factors associated with NMS burden in PD
patients
The NMSS total score (reflecting total NMS burden) correlated
significantly with disease duration (rho =0.39, p,0.0001) and
LEDD (rho =0.41, p,0.001). In a multivariate analysis of
covariance investigating age, gender, disease duration, H&Y stage
and LEDD, NMSS total score was positively associated with
LEDD (p=0.016) and H&Y stage (p=0.0012). In the domain
analysis, LEDD was positively associated with the sleep/fatigue
(p=0.017) and mood (p=0.011) domain scores.
Stratification of NMSS scores based on H&Y stage is shown in
Table 4. Sleep/fatigue, mood, gastrointestinal, sexual function
and miscellaneous domain scores were demonstrated to increase
between certain H&Y stages with statistical significance. How-
ever, it should be noted that, as described earlier, majority of the
PD patients in our study were in H&Y stages 2–3 of the disease,
and PD patients in H&Y stages 4–5 are underrepresented in our
study.
NMS that discriminated between PD patients and non-
PD subjects
Both the presence and NMSS score of each NMS were included
in the discriminative model, as a symptom due to PD may
manifest in PD patients but not progress sufficiently for its burden
to reach a threshold that discriminates between PD and non-PD
subjects. The NMS whose presence or NMSS score possessed
statistically significant discriminating power to differentiate
between PD patients and healthy controls are presented in
Table 5. For the model discriminating between PD patients and
healthy controls, the three symptoms providing the greatest
discriminative power were ‘fatigue’, ‘constipation’ and ‘dribbling
saliva’.
The NMS which discriminated between PD patients and HFS
patients with statistical significance are presented in Table 6, and
the symptoms that provided the greatest discriminative power
were ‘constipation’, ‘restless legs’ and ‘altered interest in sex’.
Symptoms whose prevalence or burden was found to signifi-
cantly discriminate between PD patients and controls as well as
between PD patients and HFS patients were ‘constipation’,
‘dribbling saliva’, ‘altered sense of taste or smell’, ‘altered interest
in sex’ and ‘restless legs’.
Discussion
This is the first NMSS study to compare the NMS burden
between PD patients, patients with a chronic neurological disease
(hemifacial spasm, HFS), and healthy controls. We demonstrated
that the overall NMS burden was significantly greater in non-
demented PD patients compared to age- and sex-matched healthy
controls, and increased NMS burden in PD applied to all domains
of the NMSS, in line with previous studies [16,17]. In PD patients,
NMS burden was positively associated with LEDD and H&Y
stage. HFS is also a chronic neurological condition, but lacks the
dopaminergic or neurodegenerative pathology that causes NMS.
Still, HFS can lead to sufficient distress to exert a psychological
effect on patients, and anxiety symptoms have previously been
shown to be increased in HFS patients [24]. Using the NMSS, we
demonstrated that overall NMS burden was also increased in HFS
Table 3. Comparisons of estimated prevalence1 (%) by NMSS domain.
Study Group
F-test
p-value Pair-wise Comparison p-values
3
PD C HFS PD vs C PD vs HFS HFS vs C
Cardiovascular domain 27.1 (63.2) 19.1 (63.3) 19.6 (64.6) 0.169 0.088 0.208 0.923
Sleep/fatigue domain 83.9 (62.6) 50.4 (64.1) 68.1 (65.4) ,0.0001 ,0.0001 0.005 0.013
Mood domain 68.6 (63.3) 33.8 (63.9) 58.8 (65.7) ,0.0001 ,0.0001 0.134 0.0005
Perceptual problems/
hallucinations domain
17.3 (62.8) 3.2 (61.4) 9.0 (63.3) 0.0005 0.0002 0.092 0.071
Attention/memory
Domain
69.6 (63.3) 56.1 (64.1) 64.7 (65.6) 0.042 0.012 0.440 0.225
Gastrointestinal domain 51.1 (63.6) 10.1 (62.5) 11.6 (63.7) ,0.0001 ,0.0001 ,0.0001 0.722
Urinary domain 67.5 (63.5) 42.8 (64.4) 53.3 (66.1) 0.0001 ,0.0001 0.042 0.166
Sexual function domain2 55.1 (64.5) 32.0 (64.9) 32.1 (66.1) ,0.0001 ,0.0001 0.002 0.985
Miscellaneous domain 67.5 (63.4) 42.0 (64.1) 42.5 (65.8) ,0.0001 ,0.0001 0.0003 0.945
PD: Parkinson’s disease patients; C: Healthy controls; HFS: Hemifacial spasm patients.
1Estimated percentages adjusted for age and sex (6 standard error) using logistic model.
2Estimated percentages adjusted for age, sex and presence of diabetes mellitus (6 standard error) using logistic regression model.
3Tukey-Kramer adjusted p-values.
doi:10.1371/journal.pone.0049596.t003
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patients compared to healthy controls. In particular, forgetting to
do things, fatigue and urinary symptoms were associated with a
higher burden in HFS patients compared to healthy controls, and
the frequencies of sleep/fatigue and mood symptoms were also
higher in HFS patients. No significant differences in the burden of
‘difficulty falling or staying asleep’ and of ‘feel nervous’ were
detected between PD patients and HFS patients despite being
found between PD patients and healthy controls. These could be
more generic symptoms found in chronic neurological diseases
that interfere with function, and therefore less specific to PD. Our
results also suggest that good control of the motor symptoms in
PD, the severity of which was positively associated with NMS
burden, remain important in minimizing NMS. Incorporating a
broader approach in empirical symptom treatment, patient
education and counselling into clinical management may provide
additional relief for the more generic NMS in patients with PD or
other chronic neurological conditions.
On the other hand, a challenge that arises in treating generic
NMS would be that of discerning the situations where the
underlying cause is really intrinsic PD pathology, and early
disease-specific treatment would be beneficial. The symptoms of
‘fatigue’, ‘difficulty falling or staying asleep’, ‘nocturia’ and ‘pain’
were found to contribute most to NMS burden on average in
subjects regardless of disease status, and investigations and
Table 4. Comparisons of PD patient group estimated NMSS scores1 by H&Y stage.
H&Y Stage Group
F-test
p-value Pair-wise Comparison p-values
2
A B C A vs B B vs C A vs C
1–1.5 222.5 325
(n=33) (n =121) (n=46)
NMSS Total 19.7 (63.0) 37.7 (62.8) 57.0 (66.9) ,0.0001 0.0003 0.004 ,0.0001
Domains
Cardiovascular domain 0.5 (60.3) 0.9 (60.2) 2.0 (62.0) 0.071 0.347 0.051 0.040
Sleep/fatigue domain 3.8 (60.7) 7.8 (60.7) 12.8 (62.0) ,0.0001 0.002 0.008 ,0.0001
Mood domain 2.9 (60.9) 9.3 (61.4) 14.5 (63.6) 0.001 0.004 0.126 ,0.0001
Perceptual problems
/Hallucinations domain
1.0 (60.7) 0.7 (60.2) 1.8 (61.0) 0.340 0.934 0.192 0.449
Attention/memory domain 2.7 (60.6) 3.5 (60.4) 4.7 (60.9) 0.204 0.345 0.536 0.091
Gastrointestinal domain 2.0 (60.7) 2.9 (60.5) 5.5 (61.4) 0.041 0.374 0.031 0.003
Urinary domain 4.0 (60.6) 5.4 (60.6) 7.2 (61.4) 0.162 0.254 0.166 0.106
Sexual function domain 0.7 (60.2) 1.4 (60.2) 1.2 (60.2) 0.040 0.016 0.426 0.062
Miscellaneous domain 2.0 (60.5) 5.5 (60.7) 6.0 (61.2) 0.002 0.003 0.722 0.0004
1Estimated mean scores adjusted for age and sex (6 standard error) using GLIM negative binomial model.
2Tukey-Kramer adjusted p-values.
doi:10.1371/journal.pone.0049596.t004
Table 5. Selection of NMSS items by stepwise logistic regression1 to discriminate between PD patients (n = 200) and healthy
controls (n = 150).










NMSS score for ‘fatigue’ 46.9 ,0.0001 0.697 1.34 [1.17, 1.54] , 0.0001
Presence of ‘constipation’ 28.0 ,0.0001 0.756 4.17 [1.83, 9.52] 0.001
Presence of ‘dribbling saliva’ 20.6 ,0.0001 0.791 23.81 [4.88, 111] , 0.001
Presence of ‘altered sense of taste
or smell’
14.6 0.0001 0.815 3.45 [1.02, 11.6] 0.046
Presence of ‘altered interest in sex’ 9.4 0.002 0.837 2.23 [1.21, 1.42] 0.010
Presence of ‘restless legs’ 10.2 0.001 0.850 3.70 [1.78, 7.63] 0.001
Presence of ‘concentration problems’ 6.8 0.009 0.858 0.27 [0.12, 0.61] 0.002
NMSS score for ‘nocturia’ 9.1 0.003 0.867 1.17 [1.04, 1.32] 0.007
Presence of ‘swallowing difficulty’ 5.8 0.016 0.873 5.52 [1.22, 25.0] 0.027
Presence of ‘excessive sweating’ 5.1 0.024 0.8812 3.75 [1.16, 12.1] 0.028
1Significance level to enter = level to stay = 0.05.
2Final model AUC = 0.881.
doi:10.1371/journal.pone.0049596.t005
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treatments for the common age-related changes or pathologies
found in an elderly population may be initiated and fail in PD
patients with such symptoms elsewhere before they come to the
attention of their movement disorder specialists. Generic NMS
resulting from intrinsic PD pathology may nevertheless have
distinguishing features, an example being dystonic pain [25].
Further characterization and elucidation of features of generic
NMS that better predict PD as the cause, and awareness of such
features amongst physicians would aid the effective management
of these NMS.
In a specialist outpatient clinic for PD patients, in addition to
addressing the non-motor symptoms that are highly prevalent in
PD patients and that cause the greatest distress, it is also important
to address those that are most specific to PD and may be more
likely to be directly caused by its pathology. Such symptoms may
be either under-diagnosed or less amenable to treatment from a
more accessible general practice. We used a stepwise logistic
regression approach to select combinations of NMS to differentiate
between i) PD patients and healthy controls, and ii) between PD
patients and HFS patients. In both models, area under the ROC
curve approached 0.90. In the model differentiating between PD
patients and healthy controls, the burden of ‘fatigue’ had the
greatest discriminative power. Fatigue may be a consequence of
deficient serotonergic function in PD [26]. In PD patients, fatigue
has also been associated with depression and sleep disturbances at
night, which may partially explain the loss of its discriminating
power for our HFS patients, who experienced more insomnia
symptoms than healthy controls. Instead, the presence of
‘constipation’ (less than 3 bowel motions per week) best
discriminated between PD and HFS patients, and also had the
second highest contribution to the area under the ROC curve in
the model discriminating between PD patients and healthy
controls. In addition to ‘constipation’, symptoms of ‘restless legs’,
‘dribbling saliva’, ‘altered interest in sex’ and ‘altered sense of taste
or smell’ (hyposmia) were statistically significant in both models.
The NMS selected in the discriminative models that were
associated with higher odds of PD could reflect a few properties:
First, they may be most specific to the NMS complex directly
caused by intrinsic PD pathology, and should be screened for in
patients even if they are not the most prevalent or severe NMS in
PD. Hyposmia and constipation, and possibly fatigue and restless
legs syndrome have been implicated as symptoms in a ‘premotor’
phase of PD that may be useful symptoms for the early diagnosis of
PD [27,28]. Second, the selected items may reflect persistent NMS
that are refractory to treatment, under-treated relative to the
general population, or influenced by dopaminergic treatment
which cannot be further optimized without compromising
satisfactory control of motor symptoms. Currently, there is no
available treatment for hyposmia in PD [3]. In addition, 51% of
the PD patients in our study experienced constipation, despite
many already being treated with laxatives. At the same time,
certain NMS may have tended not to be selected in the
discriminant models: The NMSS only rates symptoms that
occurred in the last month, and may not capture symptoms that
occur only transiently or intermittently (at intervals of more than
one month) in PD patients. For example, symptoms of hallucina-
tions, orthostatic hypotension and sleep disturbances may be
relieved by the adjustment of PD medications [29]. Certain NMS
selected in the discriminative model were associated with reduced
odds for PD, and it is possible that these were artifacts in our
dataset – their contribution to area under the ROC curve was
small.
This study had limitations. First, the NMSS scale is not intended
for diagnosis and relies on the subjective perception of symptom
severity by subjects [14]. However, it is ideal for assessing a large
number of symptoms in a reasonable amount of time while
minimizing responder fatigue. Second, PD patients with significant
cognitive impairment were excluded, preventing us from making
conclusions about this subpopulation of patients. Certain NMS,
such as apathy, hallucinations and depression have been associated
with cognitive impairment and may have not featured strongly in
this study [1,30–33]. Third, as the disability faced by patients in
the HFS group is less severe than that experienced by PD patients,
we were unable to attribute the higher NMS burden in PD
patients compared to HFS patients entirely to intrinsic PD
pathology in this study. In addition, it would be useful to obtain
quality-of-life (QoL) data for both PD and HFS patients to explore
how NMS may have a different impact on QoL in PD as opposed
Table 6. Selection of NMSS items by stepwise logistic regression1 to discriminate between PD patients (n = 200) and HFS patients
(n = 75).









Presence of ‘constipation’ 37.2 , 0.0001 0.672 37.0 [6.80, 200] , 0.0001
NMSS score for ‘restless legs’ 10.8 0.001 0.726 2.10 [1.41, 3.13] 0.001
NMSS score for ‘altered interest in sex’ 10.6 0.001 0.789 1.68 [1.15, 2.46] 0.007
Presence of ‘difficulty falling or staying asleep’ 8.5 0.004 0.811 0.15 [0.06, 0.36] ,0.0001
Presence of ‘weight change’ 9.8 0.002 0.829 17.5 [2.45, 125] 0.004
NMSS score for ‘pain’ 7.9 0.005 0.850 1.24 [1.09, 1.43] 0.002
Presence of ‘forget to do things’ 6.4 0.011 0.864 0.39 [0.19, 0.80] 0.011
NMSS score for ‘dribbling saliva’ 6.3 0.012 0.877 2.06 [1.24, 3.42] 0.005
Presence of ‘altered sense of taste or smell’ 5.7 0.017 0.887 9.09 [1.77, 45.5] 0.008
NMSS score for ‘difficulty experiencing pleasure’ 4.8 0.029 0.894 1.26 [1.05, 1.52] 0.012
Presence of ‘feel nervous’ 5.2 0.023 0.8972 0.35 [0.14, 0.88] 0.025
1Significance level to enter = level to stay = 0.05.
2Final model AUC = 0.897.
doi:10.1371/journal.pone.0049596.t006
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to HFS. Last, spouses of PD patients also participated as healthy
controls, and we may have underestimated the increased NMS
burden in PD patients if these controls’ sleep, fatigue levels and/or
mood were influenced by their spouses who had PD.
In conclusion, our study demonstrated a greater burden of non-
motor symptoms in non-demented PD patients compared to
healthy controls. We showed that certain NMS may be common
to chronic neurological diseases and lack specificity for PD,
whereas the symptoms of ‘constipation’, ‘restless legs’, ‘dribbling
saliva’, ‘altered interest in sex’ and ‘altered sense of taste or smell’
discriminated PD patients from both healthy controls and HFS
patients. Clinicians should have a high index of suspicion for NMS
in PD patients, and awareness of which symptoms are common to
chronic neurological disorders and which are more specific to PD
may help in refining treatment strategies. These would enhance
the clinical management of PD patients.
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